Patents Assigned to UNIVERSITY OF MYSORE
  • Patent number: 11292773
    Abstract: The invention relates to compounds of general formula (I): wherein R1, n, R2a, R2b, and R3 are as defined herein. The compounds are inhibitors of Bcl-2-associated death promoter (BAD) phosphorylation and have anti-apoptotic activity and are useful in the treatment of cancer, particularly breast cancer, endometrial cancer, ovarian cancer, liver cancer, colon cancer, prostate cancer or pancreatic cancer.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: April 5, 2022
    Assignees: NATIONAL UNIVERSITY OF SINGAPORE, UNIVERSITY OF MYSORE, BANGALORE UNIVERSITY
    Inventors: Peter Edward Lobie, Vijay Kumar Pandey, Rangappa Kanchugarakoppal Subbegowda, Bassappa Salundi, Mohan Chakrabhavi Dhananjaya, Shobith Rangappa, Srinivasa Venkatachalaiah
  • Publication number: 20180251425
    Abstract: The compounds of Formula (1) having topoisomerase inhibitory effect includes wherein, R1 is selected from a group consisting of H, OR5, optionally substituted C1-C12 alkyl, haloalkyl, C2-C12alkenyl, C2-C12alkynyl, C1-C12alkyloxy, C1-C12haloalkyloxy, C2-C10 heteroalkyl, C3-C12 cycloalkyl, C3-C12cycloalkenyl, C2-C12heterocycloalkyl, C2-C2 heterocycloalkenyl, C6-C18aryl, and C1-C18heteroaryl; R2, R3 and R4 are independently selected from a group consisting of H, halogen, CN, —NO2, SH, CF3, OH, CO2H, CONH2, OCF3, optionally substituted C1-C12alkyl, optionally substituted C1-C12haloalkyl optionally substituted C2-C12alkenyl, optionally substituted C2-C12alkynyl, optionally substituted C1-C12alkyloxy, optionally substituted C1-C12haloalkyloxy, optionally substituted C2-C12heteroalkyl, optionally substituted C3-C12cycloalkyl, optionally substituted C3-C12 cycloalkenyl, optionally substituted C2-C12 heterocycloalkyl, optionally substituted C2-C12 heterocycloalkenyl, optionally substituted C6-C18aryl, and optio
    Type: Application
    Filed: February 26, 2016
    Publication date: September 6, 2018
    Applicant: UNIVERSITY OF MYSORE
    Inventors: Ananda Hanumappa, Sharath Kumar Kothanahally S, Mahesh Hegde, Sathees C. Raghavan, Kanchugarakoppal S Rangappa
  • Patent number: 9604974
    Abstract: The present disclosure relates to compound of structural Formula I and a method for preparing said compounds. The disclosure further relates to a method of employing the Formula I compounds for modulation of Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway in cancer cells, and the corresponding use of compound of Formula I as anti-cancer agents.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 28, 2017
    Assignees: UNIVERSITY OF MYSORE, NATIONAL UNIVERSITY OF SINGPORE, BANGALORE UNIVERSITY, CAMBRIDGE ENTERPRISE LTD
    Inventors: Kanchugarakoppal Subbegowda Rangappa, Basappa, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, Hanumantharayappa Bharathkumar, Gautam Sethi, Andreas Bender, Peter Edward Lobie, Kam Man Hui, Alan Prem Kumar, Vijay Kumar Pandey, Julian Fuchs, Muthu Kumaraswamy Shanmugam, Krishna Bulusu, Xiaoyun Dai, Feng Li, Amudha Deivasigamani
  • Publication number: 20090312374
    Abstract: The present invention is in relation to the derivatives of 4,6-disubstituted 1,2,4-triazolo-1,3,4-thiadiazole and a process to synthesize the said derivatives. Also, the present invention was able to establish the activity of the instant derivatives against anti-cancerous activity specific to cervical and oral cancer.
    Type: Application
    Filed: September 20, 2006
    Publication date: December 17, 2009
    Applicants: UNIVERSITY OF MYSORE, JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH
    Inventors: Tapas Kumar Kundu, Kanchugarakoppal Subbegowda Rangappa, Badi Sri Sailaja, Radhika Ashish Varier, Nanjundaswamy Shivananju